Now, the shift is clear: Broader access through generics Lower costs across healthcare systems Increased competition and innovation Stronger recognition of obesity as a treatable disease This is more than a patent expiry, its a turning point in global metabolic health
Primers were designed to fit in resulting vector, pJB-HTS upstream of the hexa-histadine tag (5/phos/CCATGGGCAGCAGCCATCATCAT), and downstream (AGCTGGAATTCCTAGTTATTGCTCAGCGGTGGC) (Integrated DNA technologies) of the spacer yielding a fragment containing a phosphorylated 5 end, an initiation codon, a hexa-histadine tag, a thrombin cleavable sequence, a spacer, a termination codon, and an EcoRI site
Not everyone who applies will be approved, and not everyone who gets approved will stay enrolled
Follow-up Repeat metabolic markers after 8-12 weeks if the protocol is being continued or adjusted
Do not reuse needles or devices that are intended for single use